Zydus Wins US Nod for Celecoxib

  Published 8 months ago

Zydus Lifesciences gets USFDA nod to market Celecoxib capsules, expanding its US portfolio; US sales total $122.6 million.

  • Celecoxib treats arthritis, menstrual pain, and juvenile rheumatoid arthritis in children over 2 years old.
  • Capsules to be produced at Zydus Lifesciences’ Ahmedabad facility; boosts company’s U.S. generics business.
  • With this nod, Zydus holds 428 USFDA final approvals and has filed 492 ANDAs since FY 2003-04.

You might like these

Global Heatwave: 4 Billion Impacted by Climate Change

HDFC Life Falls on GST Cut, Q2 Profit Up

Hyundai's New Pune Plant Boosts Auto Production

CAMSPay Payment Gateway: Future-Proof Solutions for India's Dynamic Market

AI Deal Worth Rs 450 Crore

UBS Downgrades Airtel & Vodafone

Tata Motors Navigates Rare-Earth Challenges

News that matters the most ⚡